anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a lentiviral expression vector for specifically promoting high expression of CYP3A4 (cytochrome P450 3A4) gene in hepatocytes. The lentiviral expression vector for specifically promoting high expression of CYP3A4 (cytochrome P450 3A4) gene in hepatocytes comprises fundamental sequences, resistance gene sequences, multiple-cloning-site sequences, promoter subsequences, and CYP3A4 gene cDNA (complementary DNA) sequences in a pLVX-AcGFP-C1 expression vector. Multiple cloning sites include an XhoI restriction enzyme cutting site and an XmaI restriction enzyme cutting site. The CYP3A4 gene cDNA sequences include XhoI restriction enzyme cutting sites, CYP3A4 gene coded sequences and XmaI restriction enzyme cutting sites. The CYP3A4 gene cDNA sequences are forwardly inserted into the multiple-cloning-site sequences. The lentiviral expression vector is capable of expressing the CYP3A4 gene specifically, continuously, efficiently and stably with high transfection efficiency and low consumption, and can be used as a powerful tool applied to pharmaceutical research and development related to CYP3A4.
Treatment of chronic pain in patients with dementia is challenging because they have reduced ability to report pain and are particularly vulnerable to side effects of analgesics. Different types of music-based therapy have been recommended and are used as an alternative to analgesics, but the evidence is lacking. Therefore, we performed a cluster-randomized controlled study (RCT) to reduce pain intensity using music-based caregiving (MBC) over 8 weeks in nursing home patients with dementia and chronic pain. We also investigated if the amount of MBC and different chronic pain syndromes would impact on the effect. Of the 645 patients, 498 patients from 36 wards in 12 nursing homes were screened for dementia and pain. Using the Clinical Dementia Rating Scale and the Mobilization-Observation-Behavior-Intensity-Dementia Pain Scale (range 0-10), 279 (71% females, 42% severe dementia) nursing home patients were randomized to intervention group (n = 134, 18 wards) or control group (n = 145, 18 wards). The main outcome was change in pain intensity before and after the intervention. The study did not reveal any effect of MBC on pain intensity when compared with the control group (B = -0.15, 95% CI [-0.72 to 0.43]). No significant difference was found within the intervention group analyzing the impact of intervention time (B = 0.73, 95% CI [-0.55 to 2.02]) or chronic primary vs secondary pain syndromes (B = 0.45, 95% CI [-0.05 to 0.96]). Our data from this first RCT on music and pain intensity in patients with dementia and chronic pain did not find an effect of MBC on pain.
BACKGROUND: Thyroid eye disease (TED) is a condition caused by inflammatory damage to the periocular tissue that often leads to double vision. Teprotumumab is an insulin-like growth factor 1 receptor antibody that was FDA approved for the management of TED in 2020, although much is yet to be elucidated regarding its effects on diplopia outcomes among patients with TED. Diplopia is a significant and life-altering effect of TED. Previous studies have reported the effect of teprotumumab on double vision subjectively using the Gorman diplopia score. However, there is a gap in the literature addressing the effect of teprotumumab treatment on objective ocular alignment measures. The purpose of our study was to address this gap.
METHODS: We performed a retrospective review of patients who were diagnosed with TED, presented with diplopia, and treated with teprotumumab in a single-center academic ophthalmology practice. The primary outcome was change in ocular alignment in primary gaze position at 6 months (completion of teprotumumab treatment). Secondary outcomes included change in ocular alignment in other gaze positions, proptosis, eyelid position, and clinical activity score (CAS) at 6 months compared with baseline. To determine what factors may predict ocular alignment response to teprotumumab, we analyzed baseline characteristics among 3 groups, divided based on whether ocular alignment was worsened, stable, or improved at 6 months.
RESULTS: Seventeen patients met inclusion criteria, 3 (18%) worsened, 10 (59%) were stable, and 4 (24%) improved. CAS ( P = 0.02) was significantly different among the groups and was higher in those who worsened and those who improved compared with those who remained stable. Right gaze horizontal prism deviation ( P = 0.01) and left gaze horizontal prism deviation ( P = 0.03) were significantly different among the groups, with a greater degree of left gaze horizontal prism deviation in the worse group than the stable group ( P = 0.04).
CONCLUSIONS: Our study demonstrated that most patients remained stable after teprotumumab treatment regarding ocular alignment in primary gaze and the number of patients who improved was slightly higher than the number of patients who worsened after teprotumumab treatment. There are some baseline measures, such as CAS and right and left gaze horizontal prism deviation that can help better predict how a patient will respond to teprotumumab treatment. Our results can better inform physicians of how to counsel patients with TED when considering teprotumumab therapy.
The invention provides a monoclonal antibody for resisting severe acute respiratory syndrome coronavirus 2 and application thereof. The monoclonal antibody comprises: the amino acid sequence of the heavy chain variable region complementarity determining region 1 is shown in SEQ ID No. 1; the amino acid sequence of the heavy chain variable region complementarity determining region 2 is shown in SEQ ID No. 2; and a heavy chain variable region complementarity determining region 3 having the amino acid sequence shown in SEQ ID No. 3; and/or light chain variable region complementarity determining region 1 having the amino acid sequence shown in SEQ ID No. 4; light chain variable region complementarity determining region 2 having the amino acid sequence NAK; and light chain variable region complementarity determining region 3, the amino acid sequence of which is shown in SEQ ID No. 5. The ability of the monoclonal antibodies to effectively neutralize different variants, both murine and humanized versions of which protect hamsters from viral challenge with delta variants, represents a versatile and rapid strategy for generating therapeutic monoclonal antibodies for the new variant at hand.
The invention relates to the field of drug preparation and in particular relates to an application of liraglutide to preparation of drugs for treating bone lesions caused by type 2 diabetes mellitus. The application is characterized in that young DK rats are adopted as animal models; the injection frequency of liraglutide is once every day; and the injection amount is 0.6U/kg. After liraglutide is administrated for four weeks, the bone density and bone microstructure and expression of each group of osteogenic differentiation marker genes of thighbones of the rats are tested. The results show that all the parameters of either cortical bones or cancellous bones of the rats in the liraglutide adding group show that the drug has an obvious effect of reversing bone lesions caused by the hyperglycemia state. The thighbone osteogenic differentiation gene transcription level results also show that each gene expression of the rats in the GK medicine adding group is obviously improved compared with that of the rats in the GK blank group. Therefore, the results can prove that liraglutide can obviously improve bone lesions of GK rats in development of diabetes mellitus. More experimental data and scientific bases are provided for clinically using liraglutide more reasonably.
IMPORTANCE: SARS-CoV-2 infection can result in ongoing, relapsing, or new symptoms or organ dysfunction after the acute phase of infection, termed Post-Acute Sequelae of SARS-CoV-2 (PASC), or long COVID. The characteristics, prevalence, trajectory and mechanisms of PASC are poorly understood. The objectives of the Researching COVID to Enhance Recovery (RECOVER) tissue pathology study (RECOVER-Pathology) are to: (1) characterize prevalence and types of organ injury/disease and pathology occurring with PASC; (2) characterize the association of pathologic findings with clinical and other characteristics; (3) define the pathophysiology and mechanisms of PASC, and possible mediation via viral persistence; and (4) establish a post-mortem tissue biobank and post-mortem brain imaging biorepository.
METHODS: RECOVER-Pathology is a cross-sectional study of decedents dying at least 15 days following initial SARS-CoV-2 infection. Eligible decedents must meet WHO criteria for suspected, probable, or confirmed infection and must be aged 18 years or more at the time of death. Enrollment occurs at 7 sites in four U.S. states and Washington, DC. Comprehensive autopsies are conducted according to a standardized protocol within 24 hours of death; tissue samples are sent to the PASC Biorepository for later analyses. Data on clinical history are collected from the medical records and/or next of kin. The primary study outcomes include an array of pathologic features organized by organ system. Causal inference methods will be employed to investigate associations between risk factors and pathologic outcomes.
DISCUSSION: RECOVER-Pathology is the largest autopsy study addressing PASC among US adults. Results of this study are intended to elucidate mechanisms of organ injury and disease and enhance our understanding of the pathophysiology of PASC.
Multispecific molecules which induce effector cell-mediated killing of target cells are disclosed. The molecules are "multispecific" because they bind to multiple (two or more), distinct targets, one of which is an Fc receptor on the surface of an immune cell. Multispecific molecules of the invention include molecules comprised of at least one portion which binds to an Fc receptor, such as an Fc.gamma. receptor (e.g., Fc.gamma.RI) or an Fc.alpha.  receptor, and at least one other portion which binds to a different target, such as an antigen on a tumor cell or a pathogen. Multispecific molecules of the invention also include antigen "multimer complexes" comprised of multiple (i.e., two or more) portions which bind to a molecule on an antigen presenting cell (APC), such as an Fc receptor, linked to one or more antigens. These multimer complexes target antigens, such as self-antigens, to APCs to induce and/or enhance internalization (endocytosis), processing and/or presentation of the antigen by the APC. Therefore, these molecules can be used to induce or enhance an immune response either in vivo or in vitro against a normally non-immunogenic protein, such as a self-antigen. In a particular embodiment, at least one portion of the multispecific molecules comprises a humanized or human antibody or antibody fragment (e.g., ScFv or Fab') which binds to an Fc receptor or a receptor on a target cell (e.g., EGF-R or HER2).
The present invention relates to endogenous cardiac stem-progenitor cells (eCSCs). Provided herein are c-kitpos CD166pos eCSCs that are negative for the hematopoietic marker, CD45 and the mast cell marker, Tryptase. These single cell derived eCSCs can differentiate into a variety of specific cell types corresponding to the derivatives of the three germ layers. Also provided herein is a stage-specific TGF-P-Family/Wnt-Inhibitor cocktail for modulating in vitro myogenic specification and maturation of c-kitpos eCSCs. Also provided herein are methods of modulating eCSCs clonal expansion and differentiation. Also provided herein are screening assays for small organic molecules that modulate early cardiomyogenic progenitor cells. The invention further relates to the use of these modulated cells in prophylactic and therapeutic methods, including in pharmaceutical compositions of such cells, growth factors and/or small organic compounds. Finally, the invention relates to the use of such differentiated cells in transplantation and medical treatments.
PURPOSE OF REVIEW: Adenomyosis is a common cause of abnormal uterine bleeding (AUB), dysmenorrhea, and pelvic pain. Definitive diagnosis and treatment have historically been by uterine histopathology at time of hysterectomy; however, advances in imaging have supported earlier diagnosis and subsequent conservative treatment. This review aims to update the evidence supporting the uterine-sparing, procedural management options with a focus on clinical outcomes.
RECENT FINDINGS: Uterine artery embolization (UAE), radiofrequency ablation (RFA), high-intensity focused ultrasound (HIFU), percutaneous microwave ablation (PMWA), and adenomyomectomy are minimally invasive interventions proven to be effective in reducing AUB and dysmenorrhea due to adenomyosis. Symptom improvement is associated with a decrease in uterine volume. Studies support the use of alternative treatment options given the overall low rates of symptom recurrence and reintervention. Combination therapy may be more effective than monotherapy.
SUMMARY: This review provides the current evidence for use of alternative treatment options for adenomyosis. Access to ablative therapies in the USA is limited and primarily off label, given lack of FDA approval. High-quality prospective and randomized controlled trials are needed in order to further delineate treatment comparisons, efficacy, safety, and ideal patient selection for these treatments. More data are needed to assess safety and utility in those desiring future fertility.
Individuals migrating with chronic diseases often face substantial health risks, and their patterns of healthcare-seeking behavior are commonly influenced by mobility. However, to our knowledge, no research has used spatial statistics to verify this phenomenon. Utilizing data from the China Migrant Dynamic Survey of 2017, we conducted a geostatistical analysis to identify clusters of chronic disease patients among China's internal migrants. Geographically weighted regressions were utilized to examine the driving factors behind the reasons why treatment was not sought by 711 individuals among a population sample of 9272 migrant people with chronic diseases. The results indicate that there is a spatial correlation in the clustering of internal migrants with chronic diseases in China. The prevalence is highly clustered in Zhejiang and Xinjiang in north-eastern China. Hotspots were found in the northeast (Jilin and Liaoning), the north (Hebei, Beijing, and Tianjin), and the east (Shandong) and also spread into surrounding provinces. The factors that affect the migrants with no treatment were found to be the number of hospital beds per thousand population, the per capita disposable income of medical care, and the number of participants receiving health education per 1000 Chinese population. To rectify this situation, the local government should "adapt measures to local conditions." Popularizing health education and coordinating the deployment of high-quality medical facilities and medical workers are effective measures to encourage migrants to seek reasonable medical treatment.
Uterine leiomyomas may affect the performance of cell-free DNA (cfDNA)-based noninvasive prenatal testing (NIPT). We conducted a retrospective cohort study of pregnant individuals with and without leiomyomas undergoing first-trimester cfDNA-based NIPT. Characteristics of NIPT in patients with leiomyomas (n=122) were compared with those in patients without leiomyomas (n=937). Mean fetal fraction was lower in patients with leiomyomas compared with patients without (10.0% vs 11.5%; P =.001); however, the rate of indeterminate results was different only in patients without obesity (body mass index [BMI] lower than 30) (5.3% vs 1.5%; P =0.03). Total cfDNA concentration was higher in patients with leiomyomas ( P =.002), suggesting possible dilution of the fetal fraction. Leiomyoma size did not affect NIPT metrics. In conclusion, uterine leiomyomas are associated with lower fetal fraction and, in patients without obesity, with a higher rate of indeterminate results independent of leiomyoma size.
Participants from Part B who develop clinically manifest ALS may be eligible to participate in Part C. During Part C, participants who received placebo in Part B will receive tofersen 100 mg via IT injection on Days 1, 15, 29, and every 28 days thereafter up to the final maintenance dost visit. Participants who received tofersen during Part B will receive tofersen 100 mg on Days 1, 29, and every 28 days thereafter up to the final maintenance dost visit, with a dose of placebo on Day 15 to maintain the study blind. The combined duration of Part B and Part C is up to approximately 5.6 years.
Patients should inform their family members that, in the event of emergency, the treating physician or emergency room staff should be informed that the patient is physically dependent on narcotics and that the patient is being treated with SUBOXONE or SUBUTEX.

Patients should be cautioned that a serious overdose and death may occur if benzodiazepines, sedatives, tranquilizers, antidepressants, or alcohol are taken at the same time as SUBOXONE or SUBUTEX.

SUBOXONE and SUBUTEX may impair the mental or physical abilities required for the performance of potentially dangerous tasks such as driving a car or operating machinery, especially during drug induction and dose adjustment. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that buprenorphine therapy does not adversely affect their ability to engage in such activities. Like other opioids, SUBOXONE and SUBUTEX may produce orthostatic hypotension in ambulatory patients.

Patients should consult their physician if other prescription medications are currently being used or are prescribed for future use.
Volunteers are past participants who have been identified as HLA DR1501+ or DR0701+ by lab assay results. All participants will be randomized within the twin pair to receive either the seasonal quadrivalent live, attenuated influenza vaccine (LAIV4)/ FluMist® or the seasonal quadrivalent inactivated influenza vaccine (IIV4)/ Fluzone® .
A composition (i.e., a food or a drink) containing thioredoxin; and a method of protecting a digestive organ characterized by comprising taking the same. More specifically speaking, a method of protecting a digestive organ whereby the onset of stomach ulcer, etc. caused by various stresses can be prevented. By taking a food containing yeast thioredoxin at a specific concentration, stomach mucosa injury caused by various stresses, etc. (for example, ulceration on the stomach wall) can be prevented. It is desirable that the concentration of the yeast thioredoxin in a food/drink ranges from 0.01 to 1.0% by mass in the case of a food and from 0.1 to 10 μg/ml in the case of a drink.
The invention belongs to the field of nano-technology in medicine and provides a tree-like polymer targeted nano particle, a preparation method thereof and an application in cancer imaging. The general formula is PAMAM-PEG-X, wherein, PAMAM represents a tree polymer with different algebraic arborescence; PEG represents polyethylene glycol the molecular weight of which ranges from 1000 Da to 10000 Da; X represents targeted group such as folic acid, galactose, polypeptide, liposomes, or antibody. The invention also provides a new method for preparing the tree-like polymer targeted nano particle. The new method is characterized in that targeted group is connected with the tree-like polymer through the hydrophilic polyethylene glycol, thus forming a targeted composite nanostructure the size of which can be controllable. The nano particle of the invention has high biocompatibility and high targeted performance to lung cancer cells, without immunogenicity or cell toxicity and immunogenicity. The invention is of great significance in diagnostic imaging of a variety of human cancers.
The invention belongs to the technical field of administration equipment and relates to a base type microneedle array and a preparing method thereof. The base type microneedle array is perpendicular to a base and is formed by microneedles distributed evenly, wherein 100-10, 000 microneedles are arranged in each square of centimeter. The microneedles comprise medicine containing pointed ends and microneedle pedestals. The medicine containing pointed ends are made of soluble polymer colloid containing medicine ingredients. The microneedle pedestals are made of biodegradable polymer materials. Compared with the prior art, according to the designed and prepared base type microneedle array, medicine is concentrated at the upper pointed ends, due to the fact that the pointed ends are of the special geometric construction and have enough rigidity, the pointed ends can effectively pierce the stratum corneum of the surface layer of the skin by 100%, enter the hypoderm and be separated from the pedestals and left at the hypoderm to be absorbed, and thus the effects that the medicine quickly enters the hypoderm and is efficiently released are achieved. Not only is the medicine carried at the upper ends of the base type microneedle array, but also medicine carried on the pedestals of the base type microneedle array can be conveyed into the skin, the medicine loading capacity of each microneedle is greatly increased, and the administration efficiency is greatly improved.
BACKGROUND: Pressure ulcers (PUs) is ischemic necrosis caused by long-term local tissue pressure, directly affecting postoperative functional recovery. There is evidence that inflammation has an adverse impact on the development of PUs and contributes to unfavorable outcomes, suggesting that blocking the inflammatory response may be a promising therapeutic strategy for PUs. Tryptanthrin (Tryp), a natural product isolated from indigenous plants, has an anti-inflammatory biological function. However, the efficacy of Tryp in PUs remains unclear.
METHODS: Efficacy of Tryp suppressed inflammation was assessed using magnets-induced PUs model in mice. Hematoxylin-Eosin staining, masson staining and immunohistochemistry were used to evaluate the histologic changes after the formation of PUs. The expression of inflammatory cytokines was detected by qRT-PCR. And we detected the expression of protein by Western blotting.
RESULTS: Tryp could promote wound healing, such as epidermal thickening, revascularization, and nerve regeneration. Then the treatment of Tryp was able to promote fibroblast migration and collagen deposition. Moreover, Tryp attenuated inflammation through inducing macrophage polarization to M2 phenotype by suppressing the activation of cGAS-STING pathway.
CONCLUSION: Tryp could reduce the release of inflammatory cytokines, and induce RAW 264.7 polarization to M2 phenotype by targeting cGAS/STING/TBK1 pathways. In summary, Tryp may be a novel medicine for the treatment of PUs in the future.
Patients receive rituximab IV on day 1 (day 0 course 1) and bendamustine hydrochloride IV over 30 minutes on days 1-2. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover to Arm II.
Participants will be planned to participate in therapeutic lumbar exercises in groups of 5, in the morning and at noon, via the Zoom Platform in 40-minute sessions, 3 days a week, with a physiotherapist, for 6 weeks. Additionally, participants will do Rocabado's exercise at home. All exercises will be taught face to face in the first session. Online sessions with the physiotherapist will continue. A 5-minute warm-up and cool-down period and a 30-minute exercise period are planned. Patients will be asked to perform the exercises in 3 sets of 10-15 repetitions and will be allowed to rest for 10 seconds. Every exercise performed unilaterally will be performed bilaterally.